secondary outcome measures

(redirected from secondary end points)

secondary outcome measures

The outcome measures in a clinical trial that provide information on therapeutic effects of secondary importance, side effects or tolerability. Data on secondary outcomes are used to evaluate additional effects of the intervention not included in the primary outcome measure.
References in periodicals archive ?
The primary end point of the Phase II study is the anti-inflammatory effect of the drug, as determined by ALT blood levels, and the secondary end points include percentage of liver fat, as measured by MRI-PDFF.
Secondary end points slightly favored immediate dissection.
Secondary end points include assessment of mucosal injury and clinical remission.
The just ended global Phase I/II clinical test of the company's repositioned investigational drug, Galnobax successfully met both primary and secondary end points for efficiency and safety.
Treatment also was associated with significant improvements in a number of secondary end points, including a 32% reduction in pulmonary vascular resistance.
Secondary end points included change on the PTSD Checklist, the DAS (Dyadic Adjustment Scale), the BDI (Beck Depression Inventory), and the State-Trait Anxiety Inventory (JAMA 20122;308:700-9).
Secondary end points assessing sleep, depression, and hot flash--related interference with daily life also showed marked improvement in the hypnosis group.
Secondary end points were CIN of any grade, adenocarcinoma in situ (AIS), cervical cancer, vulvar cancer, or vaginal cancer related to HPV types 6, 11, 16, or 18.
Statistically significant differences emerged for three secondary end points.
The study's main end point was frequency of headache days; secondary end points were frequency of migraine days, moderate/severe headache days, monthly headache hours, and proportion of patients with a severe HIT-6 score.
In January Hypnion announced that its compound HY 10275 met the primary and secondary end points in the company's initial Phase II clinical trial at doses of 1 mg and 3 mg in adults with transient insomnia.